2024-05-08 16:12:47 ET
More on Amphastar Pharmaceuticals
- Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
- Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
- Amphastar Pharmaceuticals Q1 2024 Earnings Preview
- Amphastar a new overweight at J.P. Morgan on diverse asset portfolio
- Seeking Alpha’s Quant Rating on Amphastar Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Amphastar Pharmaceuticals Non-GAAP EPS of $1.04 beats by $0.25, revenue of $171.8M misses by $2.91M